A combination of paclitaxel and gemcitabine in an intensive dose-dense neoadjuvant chemotherapy schedule for locally advanced breast cancer

Objective: to improve the results of neoadjuvant chemotherapy (CT) in patients with locally advanced (L A) inoperable breast cancer (BC) at baseline, by using the intensified combination CT at the interval being reduced between the administration of cytostatic dru gs to 2 weeks to give a chance to t...

Full description

Bibliographic Details
Main Authors: I. V. Frai, N. I. Perevodchikova, V. P. Letyagin, V. A. Gorbunova, O. A. Anurova
Format: Article
Language:Russian
Published: ABV-press 2014-08-01
Series:Опухоли женской репродуктивной системы
Subjects:
Online Access:https://ojrs.abvpress.ru/ojrs/article/view/175
_version_ 1797876078648229888
author I. V. Frai
N. I. Perevodchikova
V. P. Letyagin
V. A. Gorbunova
O. A. Anurova
author_facet I. V. Frai
N. I. Perevodchikova
V. P. Letyagin
V. A. Gorbunova
O. A. Anurova
author_sort I. V. Frai
collection DOAJ
description Objective: to improve the results of neoadjuvant chemotherapy (CT) in patients with locally advanced (L A) inoperable breast cancer (BC) at baseline, by using the intensified combination CT at the interval being reduced between the administration of cytostatic dru gs to 2 weeks to give a chance to the patients to be surgically treated.Subjects and methods. The study enrolled 26 patients aged 33 to 75 years with L A BC. Paclitaxel was administered intravenously (IV) over 3 hours at a dose of 175 mg/m2 on day 1, followed by gemcitabine, 2000 mg/m2, given by 30-minute IV infusion on day 1 every 2 w eeks. If the cytostatics were well tolerated and their effect increased, the treatment was continued up to 6 courses.Results. Eighteen (69.2%) out of the 26 patients achieved the objective effect of treatment; of them 17 (65.4%) had a partial remission and 1 (3.8) had a complete remission.The therapeutic pathomorphism of a tumor w as rated in 22 patients; fourth-degree tumor pathomorphism w as found in 2 (9%) patien ts. The follow-up of patients w as 11 to 28 months (median, 20 months). The median time to progression w as not reached in the entire group of patients.Conclusion. A combination of paclitaxel and gemcitabine in intensive dose-dense scheduling has a marked antitumor activity in BC andis characterized by its good tolerability without a pronounced myelosuppressive effect. This therapy regimen may be used as neoadjuvant CT.
first_indexed 2024-04-10T01:57:42Z
format Article
id doaj.art-832cd4ffb0964f0d901f63e528d8aa10
institution Directory Open Access Journal
issn 1994-4098
1999-8627
language Russian
last_indexed 2024-04-10T01:57:42Z
publishDate 2014-08-01
publisher ABV-press
record_format Article
series Опухоли женской репродуктивной системы
spelling doaj.art-832cd4ffb0964f0d901f63e528d8aa102023-03-13T08:44:33ZrusABV-pressОпухоли женской репродуктивной системы1994-40981999-86272014-08-0103384410.17650/1994-4098-2011-0-3-38-44191A combination of paclitaxel and gemcitabine in an intensive dose-dense neoadjuvant chemotherapy schedule for locally advanced breast cancerI. V. Frai0N. I. Perevodchikova1V. P. Letyagin2V. A. Gorbunova3O. A. Anurova4РОНЦ им. Н.Н. Блохина РАМН, МоскваРОНЦ им. Н.Н. Блохина РАМН, МоскваРОНЦ им. Н.Н. Блохина РАМН, МоскваРОНЦ им. Н.Н. Блохина РАМН, МоскваРОНЦ им. Н.Н. Блохина РАМН, МоскваObjective: to improve the results of neoadjuvant chemotherapy (CT) in patients with locally advanced (L A) inoperable breast cancer (BC) at baseline, by using the intensified combination CT at the interval being reduced between the administration of cytostatic dru gs to 2 weeks to give a chance to the patients to be surgically treated.Subjects and methods. The study enrolled 26 patients aged 33 to 75 years with L A BC. Paclitaxel was administered intravenously (IV) over 3 hours at a dose of 175 mg/m2 on day 1, followed by gemcitabine, 2000 mg/m2, given by 30-minute IV infusion on day 1 every 2 w eeks. If the cytostatics were well tolerated and their effect increased, the treatment was continued up to 6 courses.Results. Eighteen (69.2%) out of the 26 patients achieved the objective effect of treatment; of them 17 (65.4%) had a partial remission and 1 (3.8) had a complete remission.The therapeutic pathomorphism of a tumor w as rated in 22 patients; fourth-degree tumor pathomorphism w as found in 2 (9%) patien ts. The follow-up of patients w as 11 to 28 months (median, 20 months). The median time to progression w as not reached in the entire group of patients.Conclusion. A combination of paclitaxel and gemcitabine in intensive dose-dense scheduling has a marked antitumor activity in BC andis characterized by its good tolerability without a pronounced myelosuppressive effect. This therapy regimen may be used as neoadjuvant CT.https://ojrs.abvpress.ru/ojrs/article/view/175местно-распространенный рак молочной железыdose-dense-химиотерапияпаклитакселгемцитабиннео- адъювантная химиотерапия
spellingShingle I. V. Frai
N. I. Perevodchikova
V. P. Letyagin
V. A. Gorbunova
O. A. Anurova
A combination of paclitaxel and gemcitabine in an intensive dose-dense neoadjuvant chemotherapy schedule for locally advanced breast cancer
Опухоли женской репродуктивной системы
местно-распространенный рак молочной железы
dose-dense-химиотерапия
паклитаксел
гемцитабин
нео- адъювантная химиотерапия
title A combination of paclitaxel and gemcitabine in an intensive dose-dense neoadjuvant chemotherapy schedule for locally advanced breast cancer
title_full A combination of paclitaxel and gemcitabine in an intensive dose-dense neoadjuvant chemotherapy schedule for locally advanced breast cancer
title_fullStr A combination of paclitaxel and gemcitabine in an intensive dose-dense neoadjuvant chemotherapy schedule for locally advanced breast cancer
title_full_unstemmed A combination of paclitaxel and gemcitabine in an intensive dose-dense neoadjuvant chemotherapy schedule for locally advanced breast cancer
title_short A combination of paclitaxel and gemcitabine in an intensive dose-dense neoadjuvant chemotherapy schedule for locally advanced breast cancer
title_sort combination of paclitaxel and gemcitabine in an intensive dose dense neoadjuvant chemotherapy schedule for locally advanced breast cancer
topic местно-распространенный рак молочной железы
dose-dense-химиотерапия
паклитаксел
гемцитабин
нео- адъювантная химиотерапия
url https://ojrs.abvpress.ru/ojrs/article/view/175
work_keys_str_mv AT ivfrai acombinationofpaclitaxelandgemcitabineinanintensivedosedenseneoadjuvantchemotherapyscheduleforlocallyadvancedbreastcancer
AT niperevodchikova acombinationofpaclitaxelandgemcitabineinanintensivedosedenseneoadjuvantchemotherapyscheduleforlocallyadvancedbreastcancer
AT vpletyagin acombinationofpaclitaxelandgemcitabineinanintensivedosedenseneoadjuvantchemotherapyscheduleforlocallyadvancedbreastcancer
AT vagorbunova acombinationofpaclitaxelandgemcitabineinanintensivedosedenseneoadjuvantchemotherapyscheduleforlocallyadvancedbreastcancer
AT oaanurova acombinationofpaclitaxelandgemcitabineinanintensivedosedenseneoadjuvantchemotherapyscheduleforlocallyadvancedbreastcancer
AT ivfrai combinationofpaclitaxelandgemcitabineinanintensivedosedenseneoadjuvantchemotherapyscheduleforlocallyadvancedbreastcancer
AT niperevodchikova combinationofpaclitaxelandgemcitabineinanintensivedosedenseneoadjuvantchemotherapyscheduleforlocallyadvancedbreastcancer
AT vpletyagin combinationofpaclitaxelandgemcitabineinanintensivedosedenseneoadjuvantchemotherapyscheduleforlocallyadvancedbreastcancer
AT vagorbunova combinationofpaclitaxelandgemcitabineinanintensivedosedenseneoadjuvantchemotherapyscheduleforlocallyadvancedbreastcancer
AT oaanurova combinationofpaclitaxelandgemcitabineinanintensivedosedenseneoadjuvantchemotherapyscheduleforlocallyadvancedbreastcancer